Lantern Pharma Inc. (LTRN)

Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $42.87 million. The enterprise value is $27.12 million.

Market Cap	42.87M
Enterprise Value	27.12M

Important Dates

The next estimated earnings date is Friday, November 14, 2025, after market close.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 10.80 million shares outstanding. The number of shares has decreased by -0.09% in one year.

Current Share Class	10.80M
Shares Outstanding	10.80M
Shares Change (YoY)	-0.09%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	10.81%
Float	8.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.42
P/TBV Ratio	3.42
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.01.

Current Ratio	3.52
Quick Ratio	3.26
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -88.59% and return on invested capital (ROIC) is -58.49%.

Return on Equity (ROE)	-88.59%
Return on Assets (ROA)	-48.35%
Return on Invested Capital (ROIC)	-58.49%
Return on Capital Employed (ROCE)	-163.55%
Revenue Per Employee	n/a
Profits Per Employee	-$802,029
Employee Count	24
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.75% in the last 52 weeks. The beta is 1.57, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.57
52-Week Price Change	+13.75%
50-Day Moving Average	4.18
200-Day Moving Average	3.93
Relative Strength Index (RSI)	46.03
Average Volume (20 Days)	147,519

Short Selling Information

The latest short interest is 259,396, so 2.40% of the outstanding shares have been sold short.

Short Interest	259,396
Short Previous Month	389,714
Short % of Shares Out	2.40%
Short % of Float	3.16%
Short Ratio (days to cover)	1.37

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-20.50M
Pretax Income	-19.25M
Net Income	-19.25M
EBITDA	-20.48M
EBIT	-20.50M
Earnings Per Share (EPS)	-$1.79

Balance Sheet

The company has $15.90 million in cash and $145,039 in debt, giving a net cash position of $15.76 million or $1.46 per share.

Cash & Cash Equivalents	15.90M
Total Debt	145,039
Net Cash	15.76M
Net Cash Per Share	$1.46
Equity (Book Value)	12.52M
Book Value Per Share	1.16
Working Capital	12.32M

Cash Flow

In the last 12 months, operating cash flow was -$17.87 million and capital expenditures -$7,270, giving a free cash flow of -$17.87 million.

Operating Cash Flow	-17.87M
Capital Expenditures	-7,270
Free Cash Flow	-17.87M
FCF Per Share	-$1.66

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.09%
Shareholder Yield	0.09%
Earnings Yield	-44.90%
FCF Yield	-41.69%

Analyst Forecast

The average price target for Lantern Pharma is $25.00, which is 529.72% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$25.00
Price Target Difference	529.72%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	3.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1